The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2024-11-21 DOI:10.1186/s12885-024-13116-6

Ruoyi Yang, Teng Li, Sicheng Zhang, Chunyan Shui, Hong Ma, Chao Li

{"title":"The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis.","authors":"Ruoyi Yang, Teng Li, Sicheng Zhang, Chunyan Shui, Hong Ma, Chao Li","doi":"10.1186/s12885-024-13116-6","DOIUrl":null,"url":null,"abstract":"Background: Circulating tumour DNA (ctDNA) has emerged as a valuable liquid biopsy biomarker in the field of oncology, including head and neck squamous cell carcinomas (HNSCCs), offering potential insights into cancer diagnosis, progression, and prognosis. This review aims to comprehensively evaluate the utility of ctDNA as a prognostic biomarker in HNSCC.Methods: PubMed and Ovid were searched as part of our review. Studies that investigated the relationship between ctDNA and prognosis in HNSCC patients were included. Outcomes extracted included basic characteristics, ctDNA details and survival data. Meta-analysis was performed on eligible studies to determine pooled progression-free/recurrence-free survival (RFS/PFS) and overall survival (OS).Results: Twenty-two studies were included, involving 5062 HNSCC patients from 11 countries. The meta-analysis demonstrated that the positive ctDNA/methylation detection was associated with worse OS (HR = 2.00, 95% CI 1.35-2.96) and worse PFS/RFS (HR = 3.54, 95% CI 1.05-11.85). Positive ctEBV DNA was associated with poorer OS (HR = 2.86, 95% CI 1.84-4.45) and poorer PFS/RFS (HR = 1.93, 95% CI 1.74-2.13). Positive ctHPV DNA was associated with poorer OS (HR = 1.38, 95% CI 1.07-1.38) but not PFS/PFS (HR = 1.33, 95% CI 0.96-1.85).Conclusion: Meta-analysis indicates that the status of ctDNA is significantly associated with the prognosis of HNSCC patients, with ctDNA/methylation-negative patients demonstrating better PFS/RFS and OS.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"24 1","pages":"1434"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11580464/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-024-13116-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Circulating tumour DNA (ctDNA) has emerged as a valuable liquid biopsy biomarker in the field of oncology, including head and neck squamous cell carcinomas (HNSCCs), offering potential insights into cancer diagnosis, progression, and prognosis. This review aims to comprehensively evaluate the utility of ctDNA as a prognostic biomarker in HNSCC.

Methods: PubMed and Ovid were searched as part of our review. Studies that investigated the relationship between ctDNA and prognosis in HNSCC patients were included. Outcomes extracted included basic characteristics, ctDNA details and survival data. Meta-analysis was performed on eligible studies to determine pooled progression-free/recurrence-free survival (RFS/PFS) and overall survival (OS).

Results: Twenty-two studies were included, involving 5062 HNSCC patients from 11 countries. The meta-analysis demonstrated that the positive ctDNA/methylation detection was associated with worse OS (HR = 2.00, 95% CI 1.35-2.96) and worse PFS/RFS (HR = 3.54, 95% CI 1.05-11.85). Positive ctEBV DNA was associated with poorer OS (HR = 2.86, 95% CI 1.84-4.45) and poorer PFS/RFS (HR = 1.93, 95% CI 1.74-2.13). Positive ctHPV DNA was associated with poorer OS (HR = 1.38, 95% CI 1.07-1.38) but not PFS/PFS (HR = 1.33, 95% CI 0.96-1.85).

Conclusion: Meta-analysis indicates that the status of ctDNA is significantly associated with the prognosis of HNSCC patients, with ctDNA/methylation-negative patients demonstrating better PFS/RFS and OS.

查看原文本刊更多论文

循环肿瘤DNA对头颈部鳞状细胞癌患者预后的影响：系统回顾和荟萃分析。

背景：循环肿瘤DNA（ctDNA）已成为包括头颈部鳞状细胞癌（HNSCC）在内的肿瘤学领域一种有价值的液体生物标志物，为癌症诊断、进展和预后提供了潜在的见解。本综述旨在全面评估ctDNA作为HNSCC预后生物标志物的效用：作为综述的一部分，我们检索了 PubMed 和 Ovid。方法：我们检索了PubMed和Ovid，纳入了调查HNSCC患者ctDNA与预后关系的研究。提取的结果包括基本特征、ctDNA详情和生存数据。对符合条件的研究进行荟萃分析，以确定无进展/无复发生存率（RFS/PFS）和总生存率（OS）：结果：共纳入22项研究，涉及11个国家的5062名HNSCC患者。荟萃分析表明，ctDNA/甲基化检测阳性与较差的OS（HR = 2.00，95% CI 1.35-2.96）和较差的PFS/RFS（HR = 3.54，95% CI 1.05-11.85）相关。ctEBV DNA阳性与较差的OS（HR = 2.86，95% CI 1.84-4.45）和较差的PFS/RFS（HR = 1.93，95% CI 1.74-2.13）相关。ctHPV DNA阳性与较差的OS（HR = 1.38，95% CI 1.07-1.38）相关，但与PFS/PFS（HR = 1.33，95% CI 0.96-1.85）无关：Meta分析表明，ctDNA状态与HNSCC患者的预后显著相关，ctDNA/甲基化阴性患者的PFS/RFS和OS较好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.